Atopic Dermatitis Clinical Trials

133 recruiting

Atopic Dermatitis Trials at a Glance

144 actively recruiting trials for atopic dermatitis are listed on ClinicalTrialsFinder across 6 cities in 46 countries. The largest study group is Phase 2 with 34 trials, with the heaviest enrollment activity in New York, Birmingham, and Dallas. Lead sponsors running atopic dermatitis studies include Pfizer, National Institute of Allergy and Infectious Diseases (NIAID), and Guangdong Hengrui Pharmaceutical Co., Ltd.

Browse atopic dermatitis trials by phase

Treatments under study

About Atopic Dermatitis Clinical Trials

Looking for clinical trials for Atopic Dermatitis? There are currently 133 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Atopic Dermatitis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Atopic Dermatitis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 144 trials

Recruiting
Phase 1

Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis

Atopic DermatitisLupusHyper IgE Syndrome From STAT3 Mutation+2 more
National Institute of Allergy and Infectious Diseases (NIAID)20 enrolled1 locationNCT07262983
Recruiting
Phase 2

A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis

Atopic Dermatitis
Apogee Therapeutics, Inc.350 enrolled45 locationsNCT07003425
Recruiting

This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment

Atopic Dermatitis
Sanofi1,000 enrolled43 locationsNCT07290803
Recruiting
Phase 2

A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis

Atopic Dermatitis
UCB Biopharma SRL160 enrolled50 locationsNCT07277660
Recruiting
Phase 2

A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis

Atopic Dermatitis (AD)
Bluefin Biomedicine, Inc.225 enrolled55 locationsNCT07105488
Recruiting
Phase 4

Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With Moderate/Severe Atopic Dermatitis

Sleep DisturbanceAtopic Dermatitis
Northwestern University40 enrolled1 locationNCT05042258
Recruiting
Phase 2

A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis
Kymera Therapeutics, Inc.200 enrolled61 locationsNCT07217015
Recruiting
Phase 1

A Phase 1 Study of GS101 Injection

Atopic Dermatitis (AD)
Jiangsu Genscend Biopharmaceutical Co., Ltd294 enrolled1 locationNCT07411755
Recruiting
Phase 2

Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis

Atopic Dermatitis (AD)
Enveda Therapeutics60 enrolled17 locationsNCT07298395
Recruiting

Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.

Atopic DermatitisAtopic Dermatitis, Unspecified
Pfizer150 enrolled1 locationNCT06899204
Recruiting
Phase 4

Dupilumab De-escalation in Pediatric Atopic Dermatitis

Atopic Dermatitis
Johns Hopkins University30 enrolled1 locationNCT06116526
Recruiting
Phase 3

A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis

Atopic Dermatitis
Organon and Co180 enrolled48 locationsNCT07265479
Recruiting
Phase 4

A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden

Atopic Dermatitis
Eli Lilly and Company200 enrolled66 locationsNCT07006792
Recruiting
Phase 3

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab

Atopic Dermatitis
AbbVie200 enrolled124 locationsNCT06389136
Recruiting
Phase 2

A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis

Atopic Dermatitis
Hoffmann-La Roche120 enrolled7 locationsNCT07223697
Recruiting

French Prospective Observational Study in Patients Eligible for Systemic Therapy for Atopic Dermatitis (AD)

Atopic Dermatitis
Sanofi600 enrolled60 locationsNCT06837454
Recruiting

Metabolic Profiling of Immune Responses in Immune-mediated Diseases

Atopic DermatitisPsoriasisPrimary Immunodeficiency+1 more
National Institute of Allergy and Infectious Diseases (NIAID)300 enrolled1 locationNCT04864886
Recruiting
Phase 2

A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis
Hoffmann-La Roche160 enrolled69 locationsNCT06863961
Recruiting

Studies of Skin Microbes in Healthy People and in People With Skin Conditions

Atopic DermatitisEczema
National Human Genome Research Institute (NHGRI)530 enrolled1 locationNCT00605878
Recruiting
Phase 3

A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema

Atopic Dermatitis
Pfizer500 enrolled31 locationsNCT06807281